Abstract
Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Current Vascular Pharmacology
Title: Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.
Volume: 5 Issue: 2
Author(s): Massimo Franchini and Giuseppe Lippi
Affiliation:
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Abstract: Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Export Options
About this article
Cite this article as:
Franchini Massimo and Lippi Giuseppe, Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents., Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368325
DOI https://dx.doi.org/10.2174/157016107780368325 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Protein S and Congenital Protein S Deficiency: The Most Frequent Congenital Thrombophilia in Japanese
Current Drug Targets miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Phage Choice, Isolation, and Preparation for Phage Therapy
Current Pharmaceutical Biotechnology Short Radius Centrifuges – A New Approach for Life Science Experiments Under Hyper-g Conditions for Applications in Space and Beyond
Recent Patents on Space Technology Drugs Affecting Blood Pressure Variability: An Update
Current Pharmaceutical Design Complications of Diabetes: An Insight into Genetic Polymorphism and Role of Insulin
Recent Patents on Inflammation & Allergy Drug Discovery Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research Current Status of Newer Antiinfectives
Recent Patents on Anti-Infective Drug Discovery Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Bidirectional Nature of Cardiovascular and Kidney Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Intrauterine Growth Restriction in Singleton Pregnancy-Surveillance and Delivery: An Overview
Current Women`s Health Reviews Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis
Current Pediatric Reviews Preparation and Application of Mucoadhesive Nanoparticles Containing Enoxaparin in a Wound Healing Animal Model
Current Nanoscience